Global Tofacitinib Market Size By Drug Class (Antirheumatic, Janus Kinase Inhibitor), By Application (Ulcerative Colitis, Rheumatoid Arthritis), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Geographic Scope And Forecast

Tofacitinib Market Size And Forecast

Tofacitinib Market size was valued at USD 2.34 Billion in 2022 and is projected to reach USD 5.67 Billion by 2030, growing at a CAGR of 4.7% from 2023 to 2030.

The increasing prevalence of rheumatoid arthritis, growing public awareness about the disease, rising urbanization, and increase in healthcare spending are driving the growth of the Global Tofacitinib Market significantly. The Global Tofacitinib Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Tofacitinib Market Definition

Tofacitinib, also known as Xeljanz, is a drug in the Janus kinase (JAK) inhibitor class. It works by inhibiting the activity of Janus kinase enzymes, which are involved in the inflammation that causes the symptoms of rheumatoid and psoriatic arthritis. Tofacitinib is also used to treat moderate to severe ulcerative colitis in people who cannot take certain medications or who have not responded to other treatments.

Global Tofacitinib Market Overview

The Global Tofacitinib Market is expected to experience remarkable growth in the upcoming years owing to the increasing incidence and prevalence of rheumatoid arthritis, growing public awareness about the disease, rising urbanization, and increase in healthcare spending are driving the growth of the Global Tofacitinib Market during the forecast period.

Additionally, the growing geriatric population, a robust drug pipeline, and an increase in the number of clinical trial studies will drive the Tofacitinib Market growth. Furthermore, rising government initiatives and increasing preference for as well as awareness of generic drugs will have a positive impact on the market growth rate. Moreover, the increase in R&D activities and the emergence of new markets will provide profitable growth opportunities for the Tofacitinib Market during the forecast period.

However, certain challenges and constraints are being faced, which will impede the overall market growth. Tofacitinib can cause hypercholesterolemia by raising blood cholesterol levels. It can also cause nausea, diarrhea, headache, shortness of breath, vomiting, and pale skin. All of these factors are limiting the market growth. In addition, a lack of awareness will pose additional challenges to the Tofacitinib Market during the forecast period.

Global Tofacitinib Market Segmentation Analysis

The Global Tofacitinib Market is segmented based on Drug Class, Application, Distribution Channel, and Geography.

Tofacitinib Market, By Drug Class

• Antirheumatic
• Janus Kinase Inhibitor
• Immunosuppressant

Based on Drug Class, the market is segmented into Antirheumatic, Janus Kinase Inhibitor, and Immunosuppressant. The Janus kinase inhibitor segment accounts for the highest revenue share of the Global Tofacitinib Market in 2020, and is expected to dominate the market over the forecast period owing to their wide applications in the treatment of rheumatoid arthritis and psoriasis. The medicine works by inhibiting the activity of Janus kinase enzymes, which are involved in the inflammation that causes the symptoms of rheumatoid and psoriatic arthritis. These factors are driving the growth of this segment.

Tofacitinib Market, By Application

• Ulcerative Colitis
• Rheumatoid Arthritis
• Psoriasis
• Others

Based on Application, the market is segmented into Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, and Others. The rheumatoid arthritis segment is expected to hold the largest revenue share of the Global Tofacitinib Market during the forecast period owing to the increasing demand for tofacitinib to treat rheumatic musculoskeletal disorders due to its effective analgesic and anti-inflammatory properties which will help to boost its demand in the market.

Tofacitinib Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Due to the increasing use of online pharmacy apps or websites from the comfort of customers’ homes, especially during the COVID-19 pandemic due to sudden lockdown and quarantine restrictions, the online pharmacy segment is expected to hold the largest revenue share of the Global Tofacitinib Market during the forecast period. This has further fueled the market growth of this segment.

Tofacitinib Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Geography, the Global Tofacitinib Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Among the regional markets, North America accounts for the largest revenue share in the Global Tofacitinib Market in 2020 and is expected to retain its dominance throughout the forecast period. The increased public awareness about health and wellbeing, the rise in the geriatric population, increasing healthcare spending, the large presence of major key players, high disposable income, and well-developed healthcare infrastructure in this region are all factors contributing to revenue growth in the North American market.

The market in the Asia Pacific is projected to witness expansion at a significant growth rate during the forecast period, owing to increasing incidence and prevalence of rheumatoid arthritis, increased R&D activities, and rising healthcare expenditure in the region. Furthermore, the low cost of manufacturing in China and India has led to an increase in production facilities, attracting pharmaceutical and biotechnological giants from all around the world to the Asia-Pacific region.

Key Players

The “Global Tofacitinib Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Beacon Pharmaceuticals Limited, Pfizer Inc., Globe Pharmaceuticals, Delta Pharma Limited, Mediconlife, Dolphin Pharma, Lancer Therapeuticals, Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Shandong Octagon Chemicals Limited, Zydus Cadila, Beijing Mesochem Technology Co., Ltd., Unichem Laboratories and Esteve Química.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• In February 2022, Sun Pharmaceuticals received approval from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to manufacture and market Tofacitinib ER Tablets 11mg for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis.
• In November 2021, The European Commission approved Pfizer’s XELJANZ® (tofacitinib) 5 mg twice daily for the treatment of adults with active ankylosing spondylitis (AS) who have not responded adequately to conventional therapy.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.